Geron (GERN)
(Delayed Data from NSDQ)
$4.60 USD
+0.04 (0.88%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $4.60 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
GERN 4.60 +0.04(0.88%)
Will GERN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GERN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GERN
Geron (GERN) Reports Q2 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates
GERN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Geron (GERN) to Report Q2 Earnings: What's in the Cards?
Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up
Why Is Exact Sciences (EXAS) Down 17.5% Since Last Earnings Report?
Other News for GERN
Barclays Reaffirms Their Buy Rating on Geron (GERN)
Buy Rating Affirmed for Geron Corp. on Strong Rytelo Sales and Market Potential
Geron Corporation (GERN) Q2 2024 Earnings Call Transcript
Buy Rating Affirmed for Geron’s Rytelo on Strong Launch and Positive Clinical Outlook
GERN Stock Earnings: Geron Meets EPS, Beats Revenue for Q2 2024